The historical rank and industry rank for Liwanli Innovation Co's FCF Margin % or its related term are showing as below:
TPE:3054'
s FCF Margin % Range Over the Past 10 Years
Min: -132.41 Med: -37.21 Max: 229.76
Current: -60.58
During the past 13 years, the highest FCF Margin % of Liwanli Innovation Co was 229.76%. The lowest was -132.41%. And the median was -37.21%.
TPE:3054's FCF Margin % is ranked worse than 90.08% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs TPE:3054: -60.58
Liwanli Innovation Co FCF Margin % Related Terms
Liwanli Innovation Co FCF Margin % Historical Data
* Premium members only.
The historical data trend for Liwanli Innovation Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liwanli Innovation Co (TPE:3054) has a FCF Margin % of -104.82% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Liwanli Innovation Co and its competitors. According to the industry distribution chart, Liwanli Innovation Co ranks #863 out of 958 companies in the Drug Manufacturers industry, placing it in the top 90.1%.
Is Liwanli Innovation Co's FCF Margin % too high?
Liwanli Innovation Co's current FCF Margin % is -104.82%. Based on the distribution chart, Liwanli Innovation Co ranks #863 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liwanli Innovation Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #863 out of 958 companies for FCF Margin %. This places Liwanli Innovation Co in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current FCF Margin % is -104.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.71, compared to a current price of NT$61.60 — trading 55.1% above its estimated fair value. The current FCF Margin % is -104.82%. Liwanli Innovation Co's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current FCF Margin % is -104.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be overvalued.
The current stock price of NT$61.60 is trading 55.1% above its estimated GF Value™ of NT$39.71.
GuruFocus considers Liwanli Innovation Co to be Significantly Overvalued.
Key valuation signals for TPE:3054:
FCF Margin %: -104.82%
GF Value™: NT$39.71 vs. price of NT$61.60 (55.1% above fair value)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
57GF Score
Get the complete analysis for TPE:3054
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
